Business Context and Reporting Period
This Form 8-K Current Report is filed by Palisade Bio, Inc. (Nasdaq: PALI) on July 9, 2025, covering events occurring between July 2, 2025, and July 9, 2025. The filing primarily addresses changes to the Board of Directors, including a resignation and a new appointment.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance events rather than financial performance.
Material Changes
- Director Resignation: Margery Fischbein resigned from the Board of Directors effective July 2, 2025. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Compensatory Arrangement for Resigning Director: The Board accelerated the vesting of 3,100 outstanding stock options held by Ms. Fischbein, deeming them fully vested as of July 2, 2025. The exercise period was extended through the original expiration dates.
- Director Appointment: On July 7, 2025, the Board elected Emil Chuang, MBBS FRACP, as a director to fill the vacancy. His initial term expires at the 2026 annual meeting of stockholders.
- Committee Appointments: Dr. Chuang was appointed to the Audit Committee, Compensation Committee, and Governance and Nominating Committee.
- Compensatory Arrangement for New Director: Dr. Chuang was granted a non-statutory stock option to purchase 8,000 shares of common stock. The exercise price equals the closing stock price on the date of grant. He will also receive standard non-employee director compensation as outlined in the 2024 Proxy Statement.
- Indemnification: An indemnification agreement was entered into with Dr. Chuang, consistent with agreements held by other directors and executive officers.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, outlook, or management commentary on business strategy. No new risks or contingencies were disclosed in this report. The Company confirmed that Dr. Chuang is an independent director in accordance with SEC and Nasdaq rules.
Investor Verification Checklist
- Verify the impact of the Board composition change on the Company's strategic direction and committee oversight.
- Review the 2024 Proxy Statement for details on the standard non-employee director compensation package applicable to Dr. Chuang.
- Confirm the exercise price of the 8,000 options granted to Dr. Chuang based on the closing stock price on the grant date.
- Monitor future filings for any additional changes to the Board or executive leadership.